Differences between trametinib (Megenin) chemotherapy drugs and targeted drugs and reference for clinical selection

Trametinib (Trametinib, trade name Mekinist) is a MEK inhibitor that is a typical targeted therapy drug, not a traditional chemotherapy drug. It selectively inhibits MEK1 and MEK2 kinase activities, thereby blocking key signaling pathways for tumor cell proliferation. It is especially suitable for BRAF V600 mutated melanoma and some other tumors.

Traditional chemotherapy drugs often work by killing rapidly dividing cells. Therefore, while killing cancer cells, they also damage normal cells such as bone marrow, digestive tract, and hair follicles, often leading to side effects such as hair loss, leukopenia, and severe nausea and vomiting. In contrast, the targeted drug trametinib is more selective. It acts on specific mutation signaling pathways to "precisely attack" tumor cells. Side effects are usually more controllable, and common ones are rash, diarrhea and effects on heart function.

In clinical practice, if a patient carries a BRAF V600 mutation, doctors are more likely to choose trametinib combined with a BRAF inhibitor (such as dabrafenib) for targeted therapy, because this combination can significantly prolong progression-free survival and overall survival. For patients who do not have the mutation or cannot tolerate targeted therapy, chemotherapy may still be a later-line option, but the overall efficacy is limited and the side effects are more obvious.

In general, trametinib represents a targeted drug under the concept of "precision medicine". The biggest difference from chemotherapy drugs is its mechanism of action and side effect spectrum. For people with BRAF mutations, it provides a more efficient and controllable treatment option; chemotherapy serves as a backup option when targeted or immunotherapy cannot be applied. When patients make clinical selection, they should combine genetic testing results, disease stage and physical tolerance to determine the best path under the guidance of a doctor.

Reference materials:https://www.drugs.com/